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osting by EAbstract Asthma is a common and chronic inﬂammatory condition of the airways whose cause is
not completely understood. Although many classes of drugs are used for management of asthma,
the response is variable due to multifactor reasons. This study was designed to evaluate the outcome
of using ketotifen or montelukast sodium in Iraqi asthmatic patients. Single blinded randomized
clinical trial was utilized, in which 100 asthmatic patients were recruited from Al-Karama hospital
and randomized into two groups; 1st group (50 patients, treated with ketotifen for 4 weeks) and 2nd
group (50 patients treated with montelukast sodium for 4 weeks). Asthma symptom score and
wheezing were recorded at the beginning (ﬁrst visit) and at the end of the study (after one month).
Pulmonary function tests (PFTs) were performed by spirometry, and the patients’ use of asthma
drugs and their symptoms were evaluated at each visit. The result showed that asthma symptom,
chest wheezing, and PFT values were signiﬁcantly improved in the two groups at the end of the
study compared to ﬁrst visit (p< 0.05). All symptoms were signiﬁcantly lower and PFT values were
higher in the 2nd group compared to 1st group (p< 0.05). In conclusion, both ketotifen and mont-
elukast sodium showed signiﬁcant changes in asthma symptoms and PFT after one month of treat-
ment, but the changes were more signiﬁcant with montelukast group (2nd group) compared with
ketotifen group (1st group) and this indicate that montelukast was more effective than ketotifen
in treatment of asthmatic patients.
ª 2010 King Saud University. All rights reserved.62.
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lsevier1. Introduction
Although the occurrence of asthma has increased signiﬁcantly
over the last decades in children and adults (Gibson et al.,
1998), major advances have been made in understanding the
pathophysiology of this chronic inﬂammatory disease which
leads to episodic worsening of air way function, mucus produc-
tion, cough and other symptoms (Maddox and Schwartz, 2002).
Cysteinyl leukotrienes, are important mediators of asthma,
LTs are eicosanoids derived from arachidonic acid via the
5-lipoxygenase pathway and are produced and released from
246 F.Y. Al-Hamdaniinﬂammatory cells such as eosinophils and mast cells and alve-
olar macrophages (Hay et al., 1995). They induce bronchocon-
striction, mucous secretion, increased vascular permeability
(Shield et al., 1999; Strauch et al., 2003), and by this way they
play an important role in the pathophysiology of asthma
(Mechiche et al., 2003). Antileukotriene agents, including
montelukast, zaﬁrlukast, pranlukast and the 5-lipoxygenase
inhibitor zileuton, act by blocking the effects of the cystienyl
leukotrienes (Reiss et al., 1997a; Villaran et al., 1999). Mont-
elukast sodium (sigulair) is a potent, oral-speciﬁc leukotriene
D4-receptor antagonist (cysteinyl leukotriene [Cys LT 1]-
receptor antagonist) recently approved for the treatment of
chronic asthma in patients aged 6 years and older (Reiss
et al., 1998; Krawiec and Jarjour, 2002); on the other hand,
the ﬁrst-generation H1-antihistamine ketotifen and the sec-
ond-generation H1-antihistamine cetirizine, both have anti-
allergic and anti-inﬂammatory properties and have been used
with some success in the secondary prevention of asthma
(Dyson and Mackay, 1980; Bisgaard et al., 2005). Ketotifen,
an orally active tricyclic benzocycloheptathiophene derivative,
has several properties suggesting that it might be useful in the
management of asthma. (Bustos et al., 1995) It inhibits passive
cutaneous anaphylaxis and has a mast cell stabilizing effect. It
is also a potent antihistamine speciﬁc for H1 receptors with lit-
tle anticholinergic activity and it raises intracellular cyclic-
AMP levels by inhibiting phosphodiesterase (Grant et al.,
1992). It may also interfere with the lipoxygenase pathway of
arachidonic acid metabolism (Lane, 1980). The present study
was designed to evaluate the clinical efﬁcacy of ketotifen and
montelukast sodium in treatment of Iraqi asthmatic patients.Table 1 The criteria for asthma severity score.
Symptom Frequency Score
Night wheezing None 0
Sleeping well with a little wheezing 1
Waking once at night 2
Waking most of night 3
The degree of wheezing was considered between 0 and 3 as follows:
no wheezing = 0, hardly heard wheezing = 1, moderate wheez-
ing = 2 and loud wheezing = 3.2. Patients and methods
One hundred patients with moderate asthma, were recruited
from the Asthma Clinic in Al-Karama Medical Centre and di-
vided randomly into two groups (1st group: 50 patients, 15 fe-
male, aged 45 ± 11 years), were given 1 mg ketotiﬁn (Zaditen,
Novartis) orally and (2nd group: 50 patients, 16 female, aged
40 ± 11 years) were given 10 mg montelukast (Singulair,
MSD) orally.
Inclusion criteria were: (1) Previously diagnosed asthma. (2)
Presence of two or more of the following symptoms: recurrent
wheeze, cough or chest-tightness at rest, nocturnal or early
morning wheeze, cough or chest-tightness and wheeze or
cough during exercise. (3) Forced Expiratory Volume at one
second FEV1 and Peak Expiratory Flow PEF less than 80%
predicted values. (4) No history or symptoms of cardiovascu-
lar, life threatening or uncontrolled asthma. (5) No use of oral
or parental corticosteroids within 6 weeks. (6) No pregnancy
and no use of tobacco products within the previous year. Dur-
ing the study, patients continued to take a short-acting inhaled
b2-agonist as necessary to control symptoms. All patients
signed written informed consent to participate in the study.
The study was performed in single blind manner. Medical
examination was performed and asthma symptoms were taken
at the beginning and the end of the study for each patient.
Asthma symptom score was counted according to Clinical
Asthma Score (CAS); a modiﬁcation of the Woods Downes
asthma score, to objectively evaluate our asthmatic patients’
degree of respiratory distress. This score evaluates three as-
pects of a patient’s respiratory distress: (1) degree of wheezing,(2) degree of retraction and/or ﬂaring (3) degree of dyspnea.
Each category is given a score of 0–3, so the total score ranges
from 0 to 9, with 9 being the worst score.
The degree of wheezing was considered between 0 and 3 as
follows: no wheezing = 0, hardly heard wheezing = 1, moder-
ate wheezing = 2 and loud wheezing = 3.
Pulmonary function test was also measured in the begin-
ning and at the end of the study using a spirometer with a
pneumotachograph sensor (Model ST 90, Fukuda, Sangyo
Co., Ltd., Japan). Pulmonary function testing was performed
using the acceptability standards outlined by the American
Thoracic Society (ATS) with subjects in a standing position
and wearing nose clips (ATS, 1994). All tests were carried
out between 1000 and 1700 h. Pulmonary function test was
performed three times from each subject. The highest level
for forced vital capacity (FVC), (FEV1), peak expiratory ﬂow
rate (PEFR), vital capacity (VC) were taken independently
from the three curves. The criteria for asthma severity score
were included in Table 1.
The degree of wheezing was considered between 0 and 3 as
follows: no wheezing = 0, hardly heard wheezing = 1, moder-
ate wheezing = 2 and loud wheezing = 3.
2.1. Experimental design and analysis of data
The study design was Rationalized Complete Block Design
(RCBD). The results were reported as standard error of mean
(SEM). Tukey test in comparison with unpaired t-test (2-
tailed) was used to compare between treatments groups. The
differences between the means are considered signiﬁcant at
the 5% conﬁdence level. The statistic analysis was carried
out by using SSPS 15.0. The level of signiﬁcance was set at
*, ** which represent P< 0.05 and P< 0.001, respectively.
3. Results
3.1. Asthma symptoms
All symptom scores of asthmatic patients treated according to
Clinical Asthma Score (CAS) were improved in the 2nd group
after 1 month’s treatment, (P< 0.001) for all cases, and were
signiﬁcantly reduced in the 2nd group in comparison to the 1st
group subjects at the end of the study (P< 0.001) (Table 2).
However, in the 1st group there was a small improvement in
some symptoms between the ﬁrst and last visits only
(P< 0.01 for all cases). Asthma symptoms were not different
between the 1st and 2nd groups at the start of the study. Asth-
ma severity score and chest wheezing were also improved at
the end in the 2nd group (P< 0.001 for each measure). While
Table 2 Asthma symptoms and severity in the two groups of patients at the beginning, and the end of the study.
Symptoms Pre-treatment Post-treatment
1st gr. 2nd gr. 1st gr. 2nd gr.
Night wheezing 2.12 ± 0.90 1.73 ± 0.92
NS
2.00 ± 0.98 0.19 ± 0.40
**
Night coughing 1.67 ± 1.09 1.81 ± 1.17
NS
1.25 ± 1.07 0.15 ± 0.37
**
Morning W and C 1.50 ± 1.06 1.42 ± 1.03
NS
1.21 ± 1.02 015 ± 0.37
**
Daily W, C and T 2.04 ± 0.85 1.81 ± 0.85
NS
1.79 ± 0.83 0.27 ± 0.45
**
Chest wheezing 2.33 ± 0.76 2.19 ± 0.63
NS
2.13 ± 0.80 0.31 ± 0.47
**
Asthma severity 2.67 ± 1.01 2.23 ± 0.82
NS
2.54 ± 1.02 1.00 ± 0.40
**
Gr.: group, W: wheezing, C: coughing, T: tightness of chest.
All values were quoted as means ± SEM. Statistical difference in different parameter: non signiﬁcant difference, **P< 0.001.
Gr.: group, W: wheezing, C: coughing, T: tightness of chest.
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ence in asthma severity score and chest wheezing between
the 1st and 2nd groups, at the end of the study all parameters
in the 2nd group became signiﬁcantly lower than the 1st group
(P< 0.001 for all cases), (Table 2).
3.2. Pulmonary function tests
Pulmonary function test (PFT) values were signiﬁcantly im-
proved in the two groups after 4 weeks compared to ﬁrst visit
(P< 0.05 for all measures). The improvement occurred pri-
marily within 1 month. While there was no signiﬁcant differ-
ence in PFT variables between 1st and 2nd groups (P< 0.8)
at the beginning of the study, however, the improvement was
more signiﬁcant with montelukast sodium comparing with
ketotifen, Table 3.
4. Discussion
The results of this study indicate that, after four weeks of sin-
gle-blind treatment, montelukast sodium was more effectiveTable 3 Effects of ketotifen and montelukast on pulmonary functi
FVC Pre-treatment
Post-treatment
PEFR Pre-treatment
Post-treatment
FEV Pre-treatment
Post-treatment
VC Pre-treatment
Post-treatment
FVC: forced vital capacity, PEFR: peak expiratory ﬂow rate, FEV: force
Data are expressed as means ± SEM.
n=Number of patients.
*P< 0.05 with respect to baseline value.
Pre-treatment values were not signiﬁcantly different between the two gro
Non-identical superscripts (a, b) represents signiﬁcant difference betweenthan ketotifen in improving asthma symptoms and pulmnory
function among asthmatic patients. Treatment with monteluk-
ast sodium. Resulted in signiﬁcantly greater improvements in
PFT values after only a short period of treatment. The asthma
symptom scores also improved more in the 2nd group; these
patients were almost symptom free at the end of the study.
In recent studies in adults, montelukast sodium (10 mg)
administered once daily at bed time demonstrated improve-
ment in variable of asthma control, including forced expiratory
volume in one second (FEV1) day time and nighttime symp-
tom scores, and as-needed B-agonist use (Reiss et al.,
1997b,c, 1995; National Institutes of Health, 2002). The main
aims of asthma management are to control symptoms, main-
tain pulmonary function close to a normal level and maintain
normal physical activity levels (Boskabady and Fasihfar, 2003;
National Heart, Lung, and Blood Institute, 2002).
After many years of being considered a bronchoconstrictive
disease of airway smooth muscle, asthma is now regarded as a
chronic inﬂammatory disorder of the airway (Holgate, 1997).
Even in mild to-moderate asthma, a strong inﬂammatory
process is present. This inﬂammation is believed to be theon tests.
Ketotifen (n= 50) Montelukast (n= 50)
65.06 ± 0.729 64.84 ± 0.677
75.28 ± 0.723*a 78.10 ± 0.910*b
351.73 ± 3.946 356.06 ± 3.485
397.02 ± 3.686*a 414.43 ± 4.67*b
2.41 ± 0.058 2.52 ± 0.071
2.79 ± 0.073*a 3.28 ± 0.083*b
2.79 ± 0.056 2.91 ± 0.079
3.15 ± 0.068*a 3.71 ± 0.091*b
d expiratory volume, VC: vital capacity.
ups (P> 0.05).
the two groups (P< 0.05).
248 F.Y. Al-Hamdaniunderlying cause of airway hyper-responsiveness and propen-
sity to airway obstruction (Pavord et al., 1999). In vivo studies
showed that the release of cysteinyl leukotrienes in asthmatic
patients are recovered in the airways in concentrations that
parallel asthma severity score (Hay et al., 1995). Moreover,
they have been shown to play an important role in the patho-
genesis of asthma (Barnes et al., 1998).
Montelukast is one of the leukotrienes modiﬁers (LT mod-
iﬁers) which are the ﬁrst drugs inhibiting a speciﬁc pathway or
mediator in the vast array of inﬂammatory pathways that have
established efﬁcacy in asthma (Keam et al., 2003). These LT
modiﬁers are often considered as anti-inﬂammatory and they
are associated with: (i) a decrease in fraction of exhaled nitric
oxide (FeNO) that is considered a marker of air way inﬂamma-
tion; (ii) reduced serum eosinophils; and (iii) decreased sputum
eosinophils (Rackham et al., 1989).
At the same time there was signiﬁcant improvement in PFT
observed with ketotifen comparing to the ﬁrst reading and this
was related to the fact that antihistamines such as ketotifen,
cetrizine and loratidine have shown a range of effects upon
asthma (Kabra et al., 2000; Makino, 1966), since histamine
is one of the inﬂammatory mediator within the respiratory
tract which acts as a bronchoconstrictor in patients with asth-
ma (Martin and Romer, 1977; Coyle et al., 1996), beside that
ketotifen a slow onset anti-histamine, reduced the IL-5 (one
of Type 2 T helper cell-derived cytokines which are critical in
the development and progression of allergic air way diseases.
Induced increase in the eosinophil, neutrophil, and epithelial
cell populations and pulmonary inﬂammation, especially the
desquamation of bronchial epithelial cells (Iwama et al., 1992).
Also it may slowly modulate the Th2-telated chemokine
production for later improvement of asthma, while monteluk-
ast compete with the late-asthma mediator and cause a faster
symptom release (Hung et al., 2005).
In conclusion montelukast is found more effective than
ketotifen in improving pulmonary measures and asthma-re-
lated symptoms in Iraqi asthmatic patients.References
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